CCO Infectious Disease Podcast

Key HIV Studies Influencing My Practice Following CROI 2022—Audio Recap

Episode Summary

Listen to expert insights from Daniel R. Kuritzkes, MD, and David A. Wohl, MD, on some of the most clinically relevant new data presented at CROI 2022, including prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure.

Episode Notes

In this episode, Daniel R. Kuritzkes, MD, and David A. Wohl, MD, discuss new HIV data from CROI 2022, including:

• Prevention strategies
• LA therapies
• Second-line therapies
• The VISEND study comparing dolutegravir-based antiretroviral therapy (ART) vs protease inhibitor–based ART for second-line therapy
• The NADIA study comparing dolutegravir with darunavir/ritonavir and tenofovir disoproxil fumarate with zidovudine for second-line therapy
• Comorbidities and cure
• ACTG A5324 (InMIND) study of ART intensification for cognitive impairment in people with HIV
• IMPAACT P1107 case of patient with loss of HIV-1–specific antibody response and viral detection following CCR5∆32/∆32 cord/haploidentical transplant

Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

David A. Wohl, MD
Professor of Medicine
School of Medicine
Site Leader, Global Infectious Diseases Clinical Trials Unit
University of North Carolina at Chapel Hill

Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.

Follow along with an expanded slideset at:
https://bit.ly/3CItz0Z

Link to full program:
https://bit.ly/3tSpdAx